Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
Status:
Recruiting
Trial end date:
2027-02-28
Target enrollment:
Participant gender:
Summary
A Phase II Study to Assess the Efficacy and Safety of Cadonilimab Combined With Fruquintinib
and SBRT as A third-line and Posterior Line Treatment in Patients With MSS Colorectal Cancer